Microsoft Dragon Copilot vs Suki
Both products stopped being scribes some time ago, and the question is which expansion you want and how much you can see of it. Suki adds a voice command layer over the record: a clinician can order, navigate, stage and query by speaking, and orders are staged for review rather than submitted. Dragon Copilot adds roles, evidence summaries and letters, and it publishes an account of where the models degrade. On the axes that describe how each system behaves, transparency, governance and evidence, Dragon Copilot is ahead and Suki publishes essentially nothing. On the axis that describes what the clinician can do inside the chart, Suki is ahead. Decide which failure you would rather manage: a command misheard at the order staging step, or a documentation product whose randomized efficiency result was not significant.
- It publishes how the system fails. Named limitations, a sub processor list, an explicit statement that models underperform on some accents and dialects, and honest maturity labelling of preview features. Suki publishes no model name, no accuracy figure and no governance artefact of any kind.
- Role based coverage for nurses and radiologists rather than one clinician assistant, plus multilingual multi party capture and generated referral and patient letters.
- If the estate is Microsoft, the contracting, identity and cloud relationship already exist. That is not a feature, but it is usually the reason a health system finishes this evaluation faster than it expected to.
- The voice command layer is the product and nothing else in this category matches it. A clinician can order medications, navigate the chart, stage orders and ask questions of the specific patient record by speaking, which requires write access rather than note insertion.
- Depth across record systems that competitors treat as second tier, with deep bidirectional integrations named across Epic, Oracle Health, athenahealth and MEDITECH, plus a developer platform that lets other healthcare software vendors embed the capability.
- The oversight ceiling is set in the design rather than in a disclaimer: voice commands stage orders for clinician review instead of submitting them, so a human decision sits between the model and any clinical action.
Side by Side
| Axis | M Microsoft Dragon Copilot |
S Suki |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Neither vendor publishes pricing, and Suki additionally offers no free tier and no free trial, so a clinician cannot test accuracy on their own notes before entering a sales process. Suki publishes no accuracy rate for command interpretation and no escalation behaviour for a misheard command, which is the disclosure this comparison most needs given that the command layer touches orders.
Dragon Copilot's efficiency result in the November 2025 NEJM AI randomized trial was 1.7 percent reduction in time in note and was not statistically significant; Suki has no controlled evaluation of any kind.